Short seller Andrew Left is going after Facebook
According to CNBC, the activist short seller with Citron Research is betting against the social network because it "is losing an extensive amount of relevancy."
Facebook is not a bad company, but it "just will not be a $330 billion company in a year," Left told CNBC.
Facebook shares fell as much as 1.6% in early trading.
This comes on a big news day for Silicon Valley as Microsoft announced it will acquire LinkedIn for $26.2 billion.
Left's most famous short remains Valeant Pharmaceuticals, which he called an Enron-like fraud. Since announcing the short position last October, and amid a federal investigation into its drug-pricing practices, Valeant shares have cratered 83%.
NOW WATCH: Hidden Facebook tricks you need to know
- A centenarian who starts her day with gentle exercise and loves walks shares 5 longevity tips, including staying single
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- Having an regional accent can be bad for your interviews, especially an Indian one: study
- Dirty laundry? Major clothing companies like Zara and H&M under scrutiny for allegedly fuelling deforestation in Brazil
- 5 Best places to visit near Darjeeling
- Climate change could become main driver of biodiversity decline by mid-century: Study
- RBI initiates transition plan: Small finance banks to ascend to universal banking status